|Bid||37.30 x 800|
|Ask||39.21 x 900|
|Day's range||37.31 - 38.41|
|52-week range||35.10 - 64.37|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
IONS earnings call for the period ending March 31, 2021.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -33.33% and -16.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?